Apella Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,025
Closed -$236K 350
2024
Q3
$236K Hold
2,025
0.01% 298
2024
Q2
$284K Sell
2,025
-202
-9% -$26.8K 0.01% 266
2024
Q1
$278K Buy
2,227
+232
+12% +$27.6K 0.01% 252
2023
Q4
$215K Buy
+1,995
New +$197K 0.01% 271

Other funds holding NVO

Apella Capital's NVO Position: Q4 2024 in Review

Apella Capital sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 2,025 shares — an estimated $236K sold.

Apella Capital first reported a position in NVO in Q4 2023 and held it in 4 quarters. The position peaked at $284K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Apella Capital reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Apella Capital sold 2,025 Novo Nordisk shares in Q4 2024, an estimated $236K.
  • Apella Capital first reported a position in Novo Nordisk in Q4 2023 and held it in 4 quarters.
  • Apella Capital's Novo Nordisk position peaked at $284K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Apella Capital's 13F filing for Q4 2024, filed 14 Jan 2025.